Asset Details
Do you wish to reserve the book?
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma
Do you wish to request the book?
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevalence and Clinical Impact of BRAF p.V600E Mutation in Papillary Thyroid Carcinoma
2025
Overview
Identifying risk factors in papillary thyroid carcinoma (PTC) that warrant more aggressive treatment is paramount. Importantly, the prevalence and clinical significance of
BRAF
p.V600E mutation in PTC remain debatable. This study aims to determine the association of
BRAF
p.V600E with demographic and clinicopathologic characteristics, including recurrence. Single institution data from consecutive PTC patients with
BRAF
p.V600E immunohistochemistry and/or molecular testing was collected between 2018 and 2022, including BRAF status, morphologic subtype, TN category, tumor size, nodal disease burden, tumor multifocality, extrathyroidal extension, treatment, follow-up time, loco-regional and distant recurrence, and mortality. This study included 301 patients, 30% male. The majority had
BRAF
p.V600E mutation (78.7%), and
BRAF
p.V600E was associated with morphologic subtype (
p
< 0.001), with 88% of classic subtype PTCs, 38% of PTCs with extensive follicular growth, and 100% of tall cell subtype expressing
BRAF
p.V600E.
BRAF
p.V600E was not associated with tumor size (
p
= 0.696) or nodal disease burden (
p
= 0.962). On multivariate analysis using Cox proportional hazard model, large volume nodal disease burden (HR 3.37, 95%CI 1.49–7.64,
p
= 0.004) and male gender (HR 2.29, 95%CI 1.23–4.26,
p
= 0.009) were significantly associated with recurrence.
BRAF
p.V600E (HR 0.71, 95% CI 0.31–1.65,
p
= 0.4) was not significantly associated with recurrence. In conclusion, presence of
BRAF
p.V600E in the absence of high risk histologic features does not have an impact on PTC recurrence, and thus, its utility in risk stratification is questionable in the setting of other clinicopathologic risk factors.
Publisher
Springer US,Springer Nature B.V
Subject
/ Aged
/ Cloning
/ Female
/ Humans
/ Kinases
/ Male
/ Medicine
/ Mutation
/ Neoplasm Recurrence, Local - genetics
/ Oncology
/ Patients
/ Proto-Oncogene Proteins B-raf - genetics
/ Surgery
/ Thyroid Cancer, Papillary - epidemiology
/ Thyroid Cancer, Papillary - genetics
/ Thyroid Cancer, Papillary - pathology
/ Thyroid Neoplasms - epidemiology
/ Thyroid Neoplasms - genetics
/ Thyroid Neoplasms - pathology
/ Tumors
